- BDX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $129.9 million.
- BDX has traded 542.62699999999995270627550780773162841796875 options contracts today.
- BDX is making at least a new 3-day high.
- BDX has a PE ratio of 45.
- BDX is mentioned 1.81 times per day on StockTwits.
- BDX has not yet been mentioned on StockTwits today.
- BDX is currently in the upper 20% of its 1-year range.
- BDX is in the upper 35% of its 20-day range.
- BDX is in the upper 45% of its 5-day range.
- BDX is currently trading above yesterday's high.
'Strong and Under the Radar' stocks tend to be worthwhile stocks to watch for a variety of factors including historical back testing and price action. Market technicians refer to such stocks as being in an accumulation phase before a mark-up and peak. Traders and hedge funds have frequently found that these types of stocks continue to build a solid price base and then ultimately spike higher and peak when others 'discover' how good the stock is performing. By leveraging the social discovery aspect of StockTwits we are highlighting stocks that don't currently receive much attention from retail investors, but we suspect may soon garner more attention. EXCLUSIVE OFFER: Get the inside scoop on opportunities in BDX with the Ticky from Trade-Ideas. See the FREE profile for BDX NOW at Trade-Ideas More details on BDX: Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The stock currently has a dividend yield of 1.8%. BDX has a PE ratio of 45. Currently there are 10 analysts that rate Becton Dickinson a buy, no analysts rate it a sell, and 5 rate it a hold. The average volume for Becton Dickinson has been 997,900 shares per day over the past 30 days. Becton Dickinson has a market cap of $31.6 billion and is part of the health care sector and health services industry. The stock has a beta of 1.16 and a short float of 3.3% with 7.32 days to cover. Shares are up 7.9% year-to-date as of the close of trading on Wednesday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Becton Dickinson as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Highlights from the ratings report include:
- BDX's revenue growth has slightly outpaced the industry average of 37.8%. Since the same quarter one year prior, revenues rose by 39.0%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period, despite the company's weak earnings results. Despite the fact that it has already risen in the past year, there is currently no conclusive evidence that warrants the purchase or sale of this stock.
- 46.70% is the gross profit margin for BECTON DICKINSON & CO which we consider to be strong. Despite the high profit margin, it has decreased significantly from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 5.91% trails the industry average.
- BECTON DICKINSON & CO's earnings per share declined by 45.1% in the most recent quarter compared to the same quarter a year ago. The company has reported a trend of declining earnings per share over the past year. However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, BECTON DICKINSON & CO reported lower earnings of $3.41 versus $6.00 in the prior year. This year, the market expects an improvement in earnings ($8.41 versus $3.41).
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 39.9% when compared to the same quarter one year ago, falling from $301.00 million to $181.00 million.
- You can view the full Becton Dickinson Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.